Otrivine: Quality of Life (QoL) Impact in a Real-World Setting

Inclusion Criteria

• •Participant's provision of a signed and dated electronic informed consent (eIC) form indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
• •Participant reporting a nasal congestion, and at least another common cold symptom among runny nose, sore throat, cough.
• •Participant reporting a minimum score of 5 (moderate) for plugged nose associated with common cold symptoms and at least one other symptom of common cold (at least mild score of 3) as per the WURSS-21 questionnaire at screening.
• •Participant reporting initiation of cold symptoms within no longer than 24 hours of prior to initiation of screening.
• •Participants confirm common cold symptoms within 24 hours of study product receipt of minimum score of 5 (moderate) for plugged nose associated with common cold symptoms and at least one other symptom of common cold (at least mild score of 3) as per the WURSS-21 questionnaire.
• •Male and female Participants.
• •Participant that owns a smart device and willing to download the study app.
• •Participant who is willing and able to complete all activities as shown in the Schedule of Activities independently on own smart devices.
• •Participant is in good general and mental health.
• •Participant who has a self-reported medical diagnosis of cardiovascular disease (including those with long QT syndrome), hyperthyroidism or diabetes mellitus, may be included if deemed acceptable by a medically qualified investigator.
• •Participant who is showing a strong reaction to adrenergic substances, as manifested by signs of insomnia, dizziness, tremor, cardiac arrhythmias, or elevated blood pressure, may be included if deemed acceptable by a medically qualified investigator.